Immuron Ltd
ASX:IMC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Immuron Ltd
Goodwill
Immuron Ltd
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immuron Ltd
ASX:IMC
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Goodwill
$134.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
CSL Ltd
ASX:CSL
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Goodwill
AU$185k
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Goodwill
AU$199m
|
CAGR 3-Years
230%
|
CAGR 5-Years
116%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Immuron Ltd
Glance View
Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in technology platform focused on the development and commercialization of a novel polyclonal antibodies to treat unmet medical needs. The firm operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. The firm's flagship products include Travelan & Protectyn. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn is an anti-LPS antibodies, which target and remove harmful bacteria and LPS toxins in the gut. The firm focused on clinical development of three drug candidates and several in early-stage preclinical development.
